{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:55:37Z","timestamp":1791356137139,"version":"4.3.1"},"reference-count":0,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp;amp; Research"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to determine if the range of clinical outcomes across rheumatoid arthritis patients exposed to biologic, or JAK disease\u2010modifying antirheumatic drugs (b\/tsDMARDs) remained consistent with time using the low clinical disease activity index (CDAI;range of 2.8\u201010) and remission (CDAI 0\u20102.8), along with patient\u2010reported outcomes (PROs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used baseline and prospective follow\u2010up scores from the CorEvitas registry. All patients had measurement of the CDAI and validated PROs at baseline. We examined the evolution of these outcomes to determine if there were meaningful clinical differences with time based on the range of baseline CDAI scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>6,856 patients with RA had baseline CDAI scores that were in CDAI Remission or LDA (0\u201010). 19.5% and 19.6% of patients whose baseline CDAI was between 2.8 and 6 (\u201cvery low\u201d VLDA) vs. 31.2% and 31.0% of patients with a baseline CDAI &gt;6\u201010 (\u201cHigh LDA; HLDA) exhibited a CDAI &gt;10 at 1 and 2 years respectively (p&lt;0.001for change in CDAI from baseline in the LDA subgroups). In both crude and adjusted models, patients with a CDAI between &gt;6 and 10 were almost twice as likely to have a CDAI in the moderate disease activity range at 1 and 2 years compared with patients in the range of 2.8\u20106.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The definition of CDAI so\u2010called low disease activity is likely overly broad and includes patients in the upper range of LDA with an inferior prognosis. These differences in outcomes across the range of LDA should be incorporated into therapeutic recommendations that recognize these disparate outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.80177","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:47:36Z","timestamp":1791355656000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The range of Clinical Disease Activity (CDAI) Low Disease Activity (LDA) at baseline is associated with marked differences with time in patients with Rheumatoid Arthritis (RA)"],"prefix":"10.1002","author":[{"given":"Joel M","family":"Kremer","sequence":"first","affiliation":[{"name":"Albany Medical College Emeritus The Corrona Research Foundation  Albany NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kane","sequence":"additional","affiliation":[{"name":"University of Massachusetts Lowell"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Reed","sequence":"additional","affiliation":[{"name":"University of Massachusetts Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Weinblatt","sequence":"additional","affiliation":[{"name":"The Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,6]]},"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.80177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:47:36Z","timestamp":1791355656000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.80177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":0,"alternative-id":["10.1002\/acr.80177"],"URL":"https:\/\/doi.org\/10.1002\/acr.80177","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"2026-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"acr.80177"}}